Literature DB >> 8134997

Carcinosarcoma of urinary bladder: report of 5 cases with immunohistologic study.

C Lahoti1, R Schinella, A F Rangwala, M Lee, H Mizrachi.   

Abstract

We studied 5 cases of carcinosarcoma of the urinary bladder. Immunoperoxidase studies were performed to identify the nature of the tumor and to establish the diagnosis. We suggest that these tumors represent a transition of epithelial to mesenchymal malignancy. Three of our patients had a history of radiation therapy prior to development of carcinosarcoma; of which 2 had a long interval between exposure to radiation and tumor development. Radiation is a risk factor for endometrial carcinosarcoma, and in this report we strongly suggest such an association for the urinary bladder.

Entities:  

Mesh:

Year:  1994        PMID: 8134997     DOI: 10.1016/0090-4295(94)90087-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Carcinosarcoma of the upper urinary tract with an aggressive angiosarcoma component.

Authors:  José Luis Cuadra-Urteaga; Albert Font; Gustavo Tapia; Juan Areal; Miquel Taron
Journal:  Cancer Biol Ther       Date:  2016-02-18       Impact factor: 4.742

2.  Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases.

Authors:  Jue Wang; Fen Wei Wang; Chad A Lagrange; George P Hemstreet Iii; Anne Kessinger
Journal:  Sarcoma       Date:  2010-07-18

3.  Sarcomatoid Urothelial Carcinoma: A Single Cancer Center Experience.

Authors:  Jue Wang; Caitlynn Gillaspie; Rajesh Kunadharaju; Geoffrey A Talmon; Charles Enke
Journal:  World J Oncol       Date:  2011-08-24

4.  The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience.

Authors:  Simon Paul Robinson; Assad Farooq; Marc Laniado; Hanif Motiwala
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.